

*Vienna, Austria*

Annual Congress of the  
European Association of Nuclear Medicine

October 21 –25, 2017  
Vienna, Austria

## **Pitfalls & Artefacts 6 – Interactive (Dosimetry)**

**Tuesday, October 24, 11:30-13:00**

### **Session Title**

**Pitfalls and Artefacts of Pre- and Post-Therapeutic Imaging**

### **Chairs**

Flavio Forrer (St. Gallen)

Mark Konijnenberg (Rotterdam)

### **Programme**

11:30 - 12:00 Prakash Manoharan (Manchester): An Imaging Based Guide in Individualisation of Neuroendocrine Tumour Therapy

12:00 - 12:30 Ulrike Garske (Gothenburg): Post-Therapy Imaging of the Treatment Effects After  $^{177}\text{Lu}$ -DOTA-Octreotate Therapy

12:30 - 13:00 Carlo Chiesa (Milan): Prospective Dosimetry Based Treatment Planning Based on pre- ( $^{99\text{m}}\text{Tc}$ -SPECT-CT) and post- ( $^{90\text{Y}}$  PET TOF) Radioembolisation Imaging

### **Educational Objectives**

To understand the histological grading of G1-3 Neuroendocrine Tumours and the different therapeutical options.

To get insight into the risk stratification and treatment selection for NET based on FDG and  $^{68}\text{Ga}$ -DOTATATE PET imaging.

To identify and realize the consequences of imaging artefacts that could influence the quantification of the activity after peptide receptor radionuclide therapy.

To understand and actively follow the steps involved with normal liver and tumour dosimetry for intra-arterial radioembolisation therapy of liver cancer with  $^{90\text{Y}}$ -labelled microspheres.

To understand and actively follow the steps of treatment planning and verification in radioembolisation therapy of liver cancer with  $^{90\text{Y}}$ -labeled microspheres.

### **Key Words**

neuroendocrine tumours, hepatocellular carcinoma, PRRT,  $^{68}\text{Ga}$ -DOTA-octreotate PET,  $^{90\text{Y}}$  TOF-PET,  $^{90\text{Y}}$  radioembolisation,  $^{177}\text{Lu}$ -DOTA-octreotate